Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 6 studies | 29% ± 11% |
Insufficient scRNA-seq data for expression of SULT1C4 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 99% | 454.09 | 2607 / 2642 | 99% | 54.47 | 696 / 705 |
kidney | 100% | 713.06 | 89 / 89 | 81% | 102.52 | 728 / 901 |
ovary | 100% | 1175.13 | 180 / 180 | 40% | 7.74 | 170 / 430 |
prostate | 98% | 327.50 | 241 / 245 | 32% | 7.92 | 162 / 502 |
uterus | 98% | 354.75 | 167 / 170 | 21% | 6.13 | 98 / 459 |
thymus | 100% | 270.09 | 650 / 653 | 20% | 2.44 | 119 / 605 |
lung | 100% | 668.39 | 577 / 578 | 15% | 2.41 | 179 / 1155 |
breast | 100% | 279.25 | 458 / 459 | 15% | 2.58 | 163 / 1118 |
pancreas | 66% | 76.82 | 215 / 328 | 34% | 3.79 | 60 / 178 |
adipose | 99% | 295.05 | 1194 / 1204 | 0% | 0 | 0 / 0 |
heart | 96% | 273.92 | 828 / 861 | 0% | 0 | 0 / 0 |
bladder | 90% | 187.19 | 19 / 21 | 5% | 1.37 | 23 / 504 |
intestine | 80% | 180.33 | 776 / 966 | 9% | 4.13 | 45 / 527 |
esophagus | 74% | 130.04 | 1075 / 1445 | 9% | 3.69 | 17 / 183 |
blood vessel | 79% | 140.32 | 1058 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 65% | 10.91 | 52 / 80 |
stomach | 53% | 113.68 | 192 / 359 | 9% | 2.76 | 25 / 286 |
liver | 33% | 33.34 | 74 / 226 | 17% | 12.28 | 67 / 406 |
adrenal gland | 33% | 31.67 | 86 / 258 | 9% | 1.05 | 21 / 230 |
skin | 20% | 17.79 | 359 / 1809 | 15% | 3.50 | 71 / 472 |
muscle | 31% | 26.31 | 252 / 803 | 0% | 0 | 0 / 0 |
spleen | 20% | 18.97 | 48 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0.28 | 3 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0050427 | Biological process | 3'-phosphoadenosine 5'-phosphosulfate metabolic process |
GO_0009812 | Biological process | flavonoid metabolic process |
GO_0006805 | Biological process | xenobiotic metabolic process |
GO_0006068 | Biological process | ethanol catabolic process |
GO_0051923 | Biological process | sulfation |
GO_0044598 | Biological process | doxorubicin metabolic process |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0008146 | Molecular function | sulfotransferase activity |
GO_0004062 | Molecular function | aryl sulfotransferase activity |
Gene name | SULT1C4 |
Protein name | Sulfotransferase (EC 2.8.2.-) Sulfotransferase 1C4 (ST1C4) (EC 2.8.2.1) (Sulfotransferase 1C2) (SULT1C#2) |
Synonyms | hCG_27301 SULT1C2 |
Description | FUNCTION: Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the sulfate conjugation of phenolic compounds. Can also sulfonate estrogenic compounds, however, the dietary flavonoids (phytoestrogen) and environmental estrogens, like bisphenol A are better substrates than 17beta-estradiol (E2) . Mediates the sulfation of doxorubicin and its analog epirubicin, two antitumor anthracyclines . . |
Accessions | Q6PD90 ENST00000272452.7 [O75897-1] ENST00000409309.3 [O75897-2] O75897 |